BR0008416A - Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila - Google Patents

Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila

Info

Publication number: BR0008416A
Authority: BR; Brazil
Prior art keywords: treatment; methods; potassium; resistance; cell
Prior art date: 1999-02-23

Application number

BR0008416-6A

Other languages

English (en)

Portuguese (pt)

Inventor

Grant Andrew Mc-Naughton-Smith

Gregory Gooksey Rigdon

Jonathan Walter Stocker

Original Assignee

Icagen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-23

Filing date

2000-02-10

Publication date

2002-01-29

2000-02-10 Application filed by Icagen Inc filed Critical Icagen Inc

2002-01-29 Publication of BR0008416A publication Critical patent/BR0008416A/pt

Links

ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title abstract 4
229910052700 potassium Inorganic materials 0.000 title abstract 4
239000011591 potassium Substances 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
230000015556 catabolic process Effects 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
238000006731 degradation reaction Methods 0.000 title abstract 2
238000009472 formulation Methods 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
230000002265 prevention Effects 0.000 title abstract 2
208000007056 sickle cell anemia Diseases 0.000 title abstract 2
102000004257 Potassium Channel Human genes 0.000 title 1
229940125400 channel inhibitor Drugs 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
108020001213 potassium channel Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
230000018044 dehydration Effects 0.000 abstract 1
238000006297 dehydration reaction Methods 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
239000011737 fluorine Substances 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
206010025482 malaise Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BR0008416-6A 1999-02-23 2000-02-10 Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila BR0008416A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13551199P	1999-02-23	1999-02-23
US09/386,601 US6288122B1 (en)	1999-02-23	1999-08-31	Gardos channel antagonists
PCT/US2000/003663 WO2000050026A1 (en)	1999-02-23	2000-02-10	Gardos channel antagonists

Publications (1)

Publication Number	Publication Date
BR0008416A true BR0008416A (pt)	2002-01-29

Family

ID=26833406

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR0008416-6A BR0008416A (pt)	1999-02-23	2000-02-10	Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila

Country Status (16)

Country	Link
US (1)	US6288122B1 (2)
EP (1)	EP1158971B1 (2)
JP (2)	JP4038337B2 (2)
KR (1)	KR100705726B1 (2)
CN (1)	CN1193748C (2)
AP (1)	AP1465A (2)
AT (1)	ATE370728T1 (2)
AU (1)	AU762039B2 (2)
BR (1)	BR0008416A (2)
CA (1)	CA2371857C (2)
DE (1)	DE60036093T2 (2)
ES (1)	ES2291191T3 (2)
HK (1)	HK1045262B (2)
IL (2)	IL145012A0 (2)
OA (1)	OA11838A (2)
WO (1)	WO2000050026A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003004010A1 (en) *	2001-07-06	2003-01-16	Poseidon Pharmaceuticals A/S	Carbonylamino derivatives useful for obtaining immune regulation
EP1465863B1 (en)	2002-01-04	2008-07-09	NeuroSearch A/S	Potassium channel modulators
AU2003217810C9 (en) *	2002-02-28	2008-06-12	Icagen, Inc.	Methods for treating diseases related to intraocular pressure
WO2005003143A1 (en) *	2003-07-03	2005-01-13	Poseidon Pharmaceuticals A/S	Novel potassium channel modulators
WO2005003094A1 (en) *	2003-07-03	2005-01-13	Poseidon Pharmaceuticals A/S	Diarylmethyl derivatives as potassium channel modulators
WO2006084031A1 (en) *	2005-02-01	2006-08-10	Icagen, Inc.	Imines as ion channel modulators
US20100056637A1 (en) *	2005-12-20	2010-03-04	Icagen, Inc.	Treatment methods using triaryl methane compounds
EP1968563A4 (en) *	2005-12-20	2010-05-19	Icagen Inc	TREATMENT METHODS USING TRIARYLMETHANE COMPOUNDS
PT2192896E (pt)	2007-08-24	2011-04-04	Neurosearch As	Derivados de carbonilamino úteis para o tratamento de doença inflamatória intestinal
US20090076157A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched senicapoc
EA023596B1 (ru)	2008-04-09	2016-06-30	Сирус Корпорейшн	Способы обработки композиции эритроцитов для инактивации патогена
EP2358750B1 (en)	2008-11-10	2017-01-11	Boehringer Ingelheim International GmbH	Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
WO2016134353A1 (en) *	2015-02-20	2016-08-25	Children's Medical Center Corporation	Methods for treating malaria using potassium channel inhibitors
EP3106155A1 (en)	2015-06-15	2016-12-21	Universite d'Aix Marseille	Treatment and diagnosis of hereditary xerocytosis
AU2017350760B2 (en) *	2016-10-25	2022-03-31	Paracelsus Neuroscience I, LIc	Use of senicapoc for treatment of neuropathic pain
WO2018162426A1 (en)	2017-03-06	2018-09-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Treatment and diagnosis of hereditary xerocytosis
WO2020198939A1 (zh) *	2019-03-29	2020-10-08	深圳仁泰医药科技有限公司	2,2-双(4-氟苯基)-2-苯乙酰胺的晶型a及其制备方法和应用
US12186286B2 (en) *	2019-07-29	2025-01-07	Paracelsus Neuroscience Llc	Use of senicapoc for treatment of stroke
CN115943138A (zh) *	2020-07-14	2023-04-07	阿迪玛生物有限责任公司	包含gardos通道拮抗剂的组合物及其用途
CA3201648A1 (en) *	2020-12-11	2022-06-16	Robin VAN BRUGGEN	Treatment and prevention of anaemia of inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5273992A (en)	1992-11-02	1993-12-28	Beth Israel Hospital Assoc. Inc.	Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
WO1997034589A1 (en)	1996-03-20	1997-09-25	President And Fellows Of Harvard College	Triaryl methane compounds for sickle cell disease

1999
- 1999-08-31 US US09/386,601 patent/US6288122B1/en not_active Expired - Lifetime
2000
- 2000-02-10 DE DE60036093T patent/DE60036093T2/de not_active Expired - Lifetime
- 2000-02-10 ES ES00907283T patent/ES2291191T3/es not_active Expired - Lifetime
- 2000-02-10 BR BR0008416-6A patent/BR0008416A/pt not_active IP Right Cessation
- 2000-02-10 KR KR1020017010707A patent/KR100705726B1/ko not_active Expired - Fee Related
- 2000-02-10 CN CNB008054525A patent/CN1193748C/zh not_active Expired - Fee Related
- 2000-02-10 AP APAP/P/2001/002268A patent/AP1465A/en active
- 2000-02-10 AU AU28807/00A patent/AU762039B2/en not_active Ceased
- 2000-02-10 CA CA002371857A patent/CA2371857C/en not_active Expired - Fee Related
- 2000-02-10 OA OA1200100220A patent/OA11838A/en unknown
- 2000-02-10 HK HK02106773.8A patent/HK1045262B/zh not_active IP Right Cessation
- 2000-02-10 WO PCT/US2000/003663 patent/WO2000050026A1/en not_active Ceased
- 2000-02-10 IL IL14501200A patent/IL145012A0/xx active IP Right Grant
- 2000-02-10 AT AT00907283T patent/ATE370728T1/de active
- 2000-02-10 JP JP2000600638A patent/JP4038337B2/ja not_active Expired - Fee Related
- 2000-02-10 EP EP00907283A patent/EP1158971B1/en not_active Expired - Lifetime
2001
- 2001-08-21 IL IL145012A patent/IL145012A/en not_active IP Right Cessation
2007
- 2007-05-02 JP JP2007121967A patent/JP2007262075A/ja active Pending

Also Published As

Publication number	Publication date
JP4038337B2 (ja)	2008-01-23
DE60036093T2 (de)	2008-05-15
IL145012A0 (en)	2002-06-30
KR100705726B1 (ko)	2007-04-11
AP1465A (en)	2005-09-22
AU2880700A (en)	2000-09-14
JP2007262075A (ja)	2007-10-11
AU762039B2 (en)	2003-06-19
EP1158971A4 (en)	2003-04-16
IL145012A (en)	2006-12-10
AP2001002268A0 (en)	2001-09-30
US6288122B1 (en)	2001-09-11
CA2371857A1 (en)	2000-08-31
OA11838A (en)	2005-08-22
WO2000050026A1 (en)	2000-08-31
EP1158971A1 (en)	2001-12-05
CN1344158A (zh)	2002-04-10
CN1193748C (zh)	2005-03-23
ATE370728T1 (de)	2007-09-15
HK1045262A1 (en)	2002-11-22
DE60036093D1 (de)	2007-10-04
ES2291191T3 (es)	2008-03-01
HK1045262B (zh)	2005-07-29
EP1158971B1 (en)	2007-08-22
KR20020002393A (ko)	2002-01-09
CA2371857C (en)	2008-07-29
JP2002537331A (ja)	2002-11-05

Legal Events

Date	Code	Title	Description
2009-05-12	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-12-08	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2014-01-07	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2014-12-23	B07C	Technical examination (opinion): republication [chapter 7.3 patent gazette]	Free format text: REFERENTE AO DESPACHO 7.7 PUBLICADO NA RPI 2244 DE 07/01/2014
2015-01-27	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2015-03-31	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 15A ANUIDADE.
2015-08-04	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.

Publication	Publication Date	Title
BR0008416A (pt)	2002-01-29	Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila
AP2000001934A0 (en)	2000-12-31	Antipicornaviral compounds, their preparation and use.
BR9914638A (pt)	2001-07-03	Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
BRPI0415121A (pt)	2006-11-28	material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
EA200000759A1 (ru)	2001-04-23	Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001223A1 (ru)	2001-10-22	Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BR0214343A (pt)	2004-09-14	Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EA200001224A1 (ru)	2001-08-27	Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BRPI0409417A (pt)	2006-04-25	método para usar um composto, composto, e, composição
EA200000723A1 (ru)	2001-04-23	Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
TR200001203T2 (tr)	2000-08-21	Yeni birleşik maddeler
BR0215777A (pt)	2005-03-01	Composto, método para preparar o mesmo, composição farmacêutica para prevenir e tratar cardioisquemia, cerebroisquemia, oclusão arterial cerebral e para melhorar microcirculação do cérebro, e uso do composto
BG102918A (en)	1999-09-30	Biphenylsulphanomide inhibitors of the matrix metalloproteinase
BRPI0408784A (pt)	2006-03-28	método para usar um composto
DE60329316D1 (de)	2009-10-29	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
IS7925A (is)	2005-06-30	Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
DE60045508D1 (de)	2011-02-24	Dalda-analoge und ihre verwendung
PL354030A1 (en)	2003-12-15	Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
TR200200883T2 (tr)	2002-09-23	2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
FR2889811B1 (fr)	2009-10-09	Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
ES2192832T3 (es)	2003-10-16	Uso de compuestos macrolidos para tratar glaucoma.
SE0302546D0 (sv)	2003-09-24	New compounds
TR200402529T4 (tr)	2004-12-21	Yeni Fenalliloksi fenil türevleri.
DE69935853D1 (de)	2007-05-31	Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
BRPI0612840A8 (pt)	2017-10-03	Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções